TOHO PHARMACEUTICAL
TOHO PHARMACEUTICAL CO., LTD., commonly referred to as TOHO PHARMACEUTICAL, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1948, the company has made significant strides in the development and distribution of high-quality pharmaceutical products, primarily focusing on prescription medications and over-the-counter solutions. With a strong operational presence across Asia, TOHO PHARMACEUTICAL is renowned for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic agents that cater to various medical needs, setting them apart through rigorous research and development practices. Recognised for its market leadership, TOHO PHARMACEUTICAL has achieved notable milestones, including strategic partnerships and expansions that enhance its competitive edge. The company continues to uphold its reputation for excellence in the pharmaceutical sector, contributing to improved health outcomes across the regions it serves.
DitchCarbon Score
How does TOHO PHARMACEUTICAL's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
TOHO PHARMACEUTICAL's score of 16 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
TOHO PHARMACEUTICAL's reported carbon emissions
In 2023, TOHO PHARMACEUTICAL reported total carbon emissions of approximately 553,000,000 kg CO2e. This figure includes 26,000,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 176,000,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, Scope 3 emissions accounted for about 351,000,000 kg CO2e, which encompass all other indirect emissions that occur in the value chain. Comparatively, emissions in previous years show fluctuations, with total emissions reaching approximately 575,000,000 kg CO2e in 2022, 512,000,000 kg CO2e in 2021, and 182,000,000 kg CO2e in 2020. The data indicates a significant increase in emissions from 2020 to 2021, followed by a peak in 2022 before a slight reduction in 2023. Despite these figures, TOHO PHARMACEUTICAL has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate pledges or science-based targets suggests that the company may need to enhance its climate commitments to align with industry standards and global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 34,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 191,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
TOHO PHARMACEUTICAL is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
